Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression.

Objective: Endocannabinoids have been implicated in the pathophysiology of Major Depressive Disorder (MDD) and might represent potential targets for therapeutic intervention. Objectives of the study were: (1) to measure plasma levels of endocannabinoids in a group of antidepressant-free depressed outpatients; (2) to explore their relationship with the severity of depressive symptoms as subjectively perceived by the patients; and (3) to investigate the effect of the selective serotonin reuptake inhibitor escitalopram on endocannabinoid levels.

Methods: We measured plasma levels of the two major endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anadamide), in 12 drug-free outpatients diagnosed with MDD and in 12 matched healthy controls.

Negative symptoms as key features of depression among cannabis users: a preliminary report.

Objective: Cannabis use is frequent among depressed patients and may lead to the so-called "amotivational syndrome", which combines symptoms of affective flattening and loss of emotional reactivity (i.e. the so-called "negative" symptomatology).

[The endocannabinoid system and its possible role in neurobiology of psychiatric disorders].

In the last years, numerous researches led to identify endocannabinoid system, a sophisticated short-range signaling system which is located both in Central Nervous System (CNS) and in whole organism. Because of its flexibility of expression, it plays a modulatory role in controlling the answers to stimuli which disturb homeostasis. On one hand it lets them occur whilst on the other it limits them in order to protect organism from consequences due to excessive reaction.

Pilot study of light therapy and neurocognitive performance of attention and memory in healthy subjects.

The aim of this pilot study was to investigate whether light therapy improves healthy subjects' neurocognitive performance of attention, memory, and language. Ten subjects were treated with white bright light for 5 days and a control group of 10 with no treatment were assessed with a battery of neurocognitive tests which included the Stroop Colour Word Interference Test, the Verbal Fluency Test, the Story Recall Test, and the Word Pairs Recall Test. Analysis showed improvements in cognitive scores in both groups, although on all the cognitive tests the mean difference scores between baseline and endpoint were significantly larger in the light-treated group.